Leeward Investments LLC MA Has $7.19 Million Stock Holdings in Ingevity Corporation (NYSE:NGVT)

Leeward Investments LLC MA cut its stake in shares of Ingevity Corporation (NYSE:NGVT - Free Report) by 4.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 181,523 shares of the company's stock after selling 7,824 shares during the period. Leeward Investments LLC MA owned approximately 0.50% of Ingevity worth $7,186,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of NGVT. Proficio Capital Partners LLC purchased a new position in shares of Ingevity during the fourth quarter valued at $863,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Ingevity by 6.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 646,267 shares of the company's stock valued at $26,335,000 after buying an additional 38,639 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Ingevity by 6.1% during the fourth quarter. Arizona State Retirement System now owns 10,550 shares of the company's stock valued at $430,000 after buying an additional 611 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Ingevity during the fourth quarter valued at $3,018,000. Finally, PNC Financial Services Group Inc. grew its stake in Ingevity by 6.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 12,097 shares of the company's stock valued at $493,000 after purchasing an additional 765 shares in the last quarter. Hedge funds and other institutional investors own 91.59% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen upgraded Ingevity from a "buy" rating to a "strong-buy" rating in a research note on Friday, June 6th. Wells Fargo & Company boosted their target price on Ingevity from $32.00 to $38.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $52.75.

Ingevity Stock Up 3.3%

NYSE NGVT traded up $1.51 on Tuesday, reaching $46.85. The stock had a trading volume of 300,162 shares, compared to its average volume of 276,400. The business has a 50 day moving average price of $41.92 and a 200 day moving average price of $41.37. The company has a current ratio of 2.00, a quick ratio of 1.08 and a debt-to-equity ratio of 5.68. Ingevity Corporation has a 1 year low of $28.49 and a 1 year high of $51.67. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -4.81 and a beta of 1.38.

Ingevity (NYSE:NGVT - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.25. The company had revenue of $284.00 million during the quarter, compared to the consensus estimate of $299.13 million. Ingevity had a positive return on equity of 63.76% and a negative net margin of 26.20%. The firm's revenue was down 16.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.47 EPS. On average, analysts forecast that Ingevity Corporation will post 4.45 EPS for the current fiscal year.

Ingevity Company Profile

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.